Does Blue Cross Blue Shield Cover Trelegy?
The verdict
Covered on most plans
Blue Cross Blue Shield plans generally cover Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) as a brand maintenance inhaler for COPD and asthma — but BCBS is not one plan, it is a federation of 30-plus independent licensees. Tier placement, prior authorization, and step-therapy requirements vary by your specific Blue plan. Trelegy is brand-only with no generic, so the coverage variable is PA or step therapy, not generic substitution. Always verify with your specific Blue plan's drug lookup.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Blue Cross Blue Shield using your member ID.
Key facts
Blue Cross Blue Shield is a federation of 30-plus independent licensees — Trelegy tier, PA, and step-therapy requirements vary by the specific Blue plan you hold.
Blue Cross Blue Shield Association, licensee information
Trelegy Ellipta is brand-only (no FDA-approved generic as of 2026), making it categorically different from Symbicort, which has a widely preferred generic.
FDA drug labeling, Trelegy Ellipta
The 2026 Medicare Part D $2,100 out-of-pocket cap limits annual drug spending for Medicare enrollees, including those on BCBS Medicare plans with Trelegy on formulary.
CMS, Medicare Part D 2026 benefit parameters
Medicare vs. commercial coverage
Whether Blue Cross Blue Shield covers Trelegy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
BCBS Medicare Advantage and Medicare Supplement plans generally cover Trelegy Ellipta for COPD and asthma as a covered brand inhaler. The 2026 Medicare Part D $2,100 out-of-pocket cap applies to covered drugs including Trelegy on BCBS Medicare Part D plans. No generic exists, so there is no generic-substitution tier edit — the coverage variable is whether a given BCBS Medicare licensee attaches prior authorization or step therapy. Verify on your specific Blue Medicare plan's formulary, since PA and step-therapy rules differ by licensee.
Commercial / Employer
Group & marketplace plans
BCBS commercial/employer plans generally cover Trelegy Ellipta as a brand inhaler, but tier, prior authorization, and step-therapy requirements vary by the specific BCBS licensee in your state. ACA/individual plans administered by BCBS licensees also generally cover Trelegy at the brand tier with possible step therapy. Medicaid managed-care plans operated by BCBS-affiliated entities cover Trelegy per state PDL, with prior authorization and step therapy common for a brand-only triple-therapy inhaler. BCBS is a federation — there is no single national BCBS tier or PA rule. Verify on your specific Blue plan's drug lookup.
The 3 boxes you must tick to get approved
Commercial plans that will consider Trelegy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Trelegy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$802–$918 per inhaler (30-day supply)
List price with no coverage — before any manufacturer savings card.
With coverage
Varies by BCBS licensee plan tier — confirm with your specific Blue plan's drug lookup. Medicare Part D cost-share subject to the 2026 $2,100 OOP cap.
Typical monthly copay once prior authorization is approved.
Bridge program
GSK (Trelegy manufacturer) offers the myGSK Assistance Program for eligible uninsured and underinsured patients. Verify eligibility at gsk.com.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. No generic alternative exists for Trelegy. Actual cost-share depends on which BCBS licensee you have, plan tier, and deductible status. Verify on your Blue plan's drug lookup or call the member services number on your ID card.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Identify your specific BCBS licensee and use its drug lookup
Go to the website for your specific Blue plan (not a generic BCBS site) and use the formulary or 'Find a Drug' tool. Enter 'Trelegy Ellipta' and your plan ID to see tier, PA status, and step-therapy requirements. Because BCBS is 30-plus independent plans, the result will differ by which Blue you have.
- 2
Call the member services number on your Blue ID card
Call and ask specifically: Is Trelegy Ellipta on my formulary? Is prior authorization or step therapy required? What tier is it, and what is my expected cost-share for a 30-day supply?
- 3
Ask your prescriber to initiate PA if required
If your BCBS plan requires prior authorization or step-therapy documentation, your prescriber can submit clinical notes confirming COPD or asthma diagnosis and prior inhaler history directly to your Blue plan's PA department.
Options if Blue Cross Blue Shield won't cover Trelegy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Anoro Ellipta (umeclidinium/vilanterol)
Dual-agent LABA/LAMA inhaler (no ICS); may be covered at a lower tier on some BCBS plans where a dual agent is clinically appropriate.
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol)
Another brand triple-therapy COPD inhaler; tier and UM vary by BCBS licensee — may or may not differ from Trelegy on your specific plan.
Generic fluticasone-salmeterol (ICS/LABA)
A generic dual-agent ICS/LABA combination; may be covered at a lower tier as a step-therapy option on some BCBS plans where triple therapy is not yet documented.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Most BCBS plans cover Trelegy Ellipta as a brand inhaler, but because BCBS is 30-plus independent licensees, the answer depends on which Blue plan you have. Some licensees cover Trelegy with no prior authorization; others require step therapy. There is no single national BCBS answer. Check your specific Blue plan's drug lookup tool or call member services — verifying with your actual plan is the only reliable way to confirm coverage and cost-share.
No. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is brand-only — no FDA-approved generic exists as of 2026. Unlike Symbicort, where a generic (budesonide/formoterol) is widely preferred, there is no generic Trelegy for BCBS plans to substitute. The coverage question is whether the brand inhaler is approved under your specific Blue licensee's tier and utilization management rules.
Yes. The 2026 Medicare Part D $2,100 beneficiary out-of-pocket cap applies to covered Part D drugs including Trelegy on BCBS Medicare Advantage and Medicare Part D plans. Once you reach that cap, you pay $0 for covered Part D drugs for the rest of the year. The cap applies regardless of which BCBS Medicare plan you have, though cost-share before hitting the cap depends on your plan's tier for Trelegy. Verify in your plan's Evidence of Coverage.
Trelegy was selected by CMS for Medicare drug price negotiation in a later cohort — not the first 10 drugs whose negotiated prices took effect in 2026. A government-negotiated price for Trelegy was not in effect as of 2026. Do not assume any negotiated-price discount applies on your BCBS Medicare plan in 2026. Verify the current status against the CMS selected-drug list before assuming any savings.
The key difference is generic availability. Symbicort has an FDA-approved generic (budesonide/formoterol) that BCBS plans widely prefer at a lower tier — brand Symbicort is frequently non-preferred or not covered on Part D. Trelegy is brand-only with no generic, so the coverage question is PA or step therapy rather than generic substitution. Both are BCBS covered inhaler classes, but the coverage pathway is structurally opposite.
Related Articles
Does BCBS Michigan Cover Contrave? 2026 MI Guide | Curex
BCBS Michigan upheld weight-loss exclusions (DIFS 2025). Contrave is plan-dependent. MI Medicaid favors weight-loss GLP-1s; Contrave varies by PDL.
Read moreDoes BCBS of Illinois Cover Jardiance? 2026
BCBS of Illinois (HCSC) covers Jardiance across commercial, ACA, Medicare, and Medicaid. Metformin-first step is common. 2026 MFP $197 for Medicare.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Blue Cross Blue Shield of Minnesota Cover Mounjaro? 2026 | Curex
BCBS of Minnesota covers Mounjaro for type 2 diabetes with PA — not weight loss. MN Medicaid covers weight-loss GLP-1s for Zepbound, not Mounjaro.
Read moreDoes Blue Cross Blue Shield Cover Ambien? 2026 | Curex
Blue Cross Blue Shield covers generic zolpidem (Tier 1–2); brand Ambien is non-preferred. Quantity limits apply. Verify your specific BCBS plan for 2026.
Read moreDoes BCBS of Texas Cover Ozempic? 2026 Guide | Curex
BCBS Texas (HCSC) covers Ozempic for T2D with PA — not weight loss. HCSC shares PA with BCBS IL. TX Medicaid uses separate Star MCOs. Verify on BCBS TX.
Read moreThis content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Blue Cross Blue Shield before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.